|
ENGN enGene Therapeutics Inc 1980845 |
| Income Statement |
|
Net Income
|
2026-07-31
|
$-32,501,000.00 |
| Balance Sheet |
|
Current Assets
|
$277,900,000.00 |
|
Assets
|
$288,322,000.00 |
|
Current Liabilities
|
$27,209,000.00 |
|
Liabilities
|
$58,032,000.00 |
|
Equity
|
$230,290,000.00 |
|
Shares Out
|
67014067.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-78,347,000.00 |
|
Investing Cash Flow
|
$-72,538,000.00 |
| Market Analysis |
Market Cap
|
$118,614,898.59 |
|
Price
|
$1.77 |
|
BVPS
|
3.44 |
|
PB
|
0.51 |
|
EPS
|
-0.47 |
|
FCF
|
$-78,598,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:50 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:40 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ENGN documents filed with the SEC.
ENGN Filings
Clear
